Table 4: Linear regressions for corneal hysteresis and self-reported disorders of the thyroid gland, pituitary gland or other immunological/systemic disorders[†]

Corneal Hysteresis	Model 1[§]		Model 2[§]		Model 3[§]		Prevalence [‡]
	Coef.(β)	p	Coef.(β)	p	Coef.(β)	p	
Thyroid disorders							
Hyperthyroidism/thyrotoxicosis/Grave's disease	-0.02 (-0.16,0.12)	0.74	-0.02 (-0.16,0.12)	0.75	-0.04 (-0.18,0.10)	0.61	1.05%(0.94%)
Hypothyroidism/myxoedema	0.02 (-0.04,0.07)	0.57	0.02 (-0.03,0.08)	0.43	0.02 (-0.03,0.08)	0.42	6.46%(6.50%)
Thyroid goitre	-0.22(-0.43,-0.01)	0.04*	-0.22 (-0.43,-0.02)	0.04*	-0.19 (-0.39,0.02)	0.07	0.13%(0.40%)
Thyroiditis	0.20 (-0.26,0.66)	0.40	0.20 (-0.26,0.66)	0.39	0.21 (-0.24,0.67)	0.36	0.07%(0.09%)
Disorders of pituitary gland							
Acromegaly	1.09 (0.12,2.06)	0.03*	1.11 (0.15,2.07)	0.02*	1.22 (0.21,2.22)	0.02*	0.02%(0.02%)
Hypopituitarism	-0.25 (-0.82,0.32)	0.40	-0.26 (-0.83,0.31)	0.38	-0.24 (-0.80,0.33)	0.42	0.05%(0.06%)
Hyperprolactinemia	-0.06 (-0.87,0.75)	0.89	-0.03 (-0.87,0.81)	0.95	-0.03 (-0.84,0.78)	0.95	0.02%(0.02%)
Pituitary adenoma/tumour	-0.09 (-0.51,0.34)	0.69	-0.07 (-0.49,0.35)	0.74	-0.02 (-0.44,0.39)	0.92	0.09%(0.10%)
Immunological/systemic disorders							
Systemic lupus erythematosus (SLE)	0.64 (0.31,0.96)	0.0001**	0.64 (0.32,0.97)	0.0001**	0.55 (0.24,0.86)	0.0006**	0.17%(0.16%)
Sjogren's syndrome/sicca syndrome	0.10 (-0.29,0.48)	0.63	0.11 (-0.28,0.50)	0.58	0.13 (-0.26,0.52)	0.51	0.13%(0.11%)
Rheumatoid arthritis	0.11 (-0.01,0.24)	0.07	0.12 (0.00,0.24)	0.06	0.08 (-0.04,0.20)	0.20	1.51%(1.25%)
Vasculitis	0.04 (-0.19,0.27)	0.72	0.05 (-0.18,0.27)	0.68	0.07 (-0.16,0.30)	0.56	0.37%(0.39%)
Dermatopolymyositis	-0.24 (-1.02,0.54)	0.54	-0.25 (-1.02,0.52)	0.52	-0.26 (-1.05,0.52)	0.51	0.03%(0.02%)
Scleroderma/systemic sclerosis	0.04 (-0.62,0.71)	0.90	0.03 (-0.63,0.70)	0.92	0.07 (-0.55,0.70)	0.82	0.04%(0.03%)
Psoriasis	0.10 (-0.03,0.22)	0.12	0.10 (-0.03,0.22)	0.13	0.07 (-0.06,0.19)	0.28	1.49%(1.32%)
Sarcoidosis	-0.29 (-0.56,-0.01)	0.04*	-0.27 (-0.55,0.01)	0.06	-0.18 (-0.46,0.11)	0.22	0.27%(0.26%)

† Participants with self-reported glaucoma in either eye were excluded

*$p<0.05$ ** $p<0.003125$ (Bonferroni-corrected threshold for multiple testing)

§ Model I, adjusted for age, sex and ethnicity; Model II, adjusted for age, sex, ethnicity and Goldmann-correlated intraocular pressure (IOPg); Model III, adjusted for age, sex, ethnicity, IOPg, height, diastolic blood pressure, visual acuity, smoking status, refractive error, diabetes status and Townsend deprivation index.

‡ Prevalence %= Proportion using all UK Biobank participants with available data (n=375,064)

(%) = Proportion within the sample with available data after data cleaning.(n=69,973)